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Introduction {#sec004}
============

Envenoming from snakebites is a public health problem in rural areas of the tropical and subtropical countries in Africa, Latin America, Asia and Oceania \[[@pntd.0007017.ref001], [@pntd.0007017.ref002]\]. This medical condition kills more than 95,000 people per year and leads over 300,000 victims to live with permanent sequelae \[[@pntd.0007017.ref003]\].

It is also estimated that there are approximately 3,700 species of snakes worldwide \[[@pntd.0007017.ref004]\]. Of these, approximately 15% are venomous and have caused serious accidents involving humans and other animals \[[@pntd.0007017.ref005]\]. Venomous snakes belong to the Colubroidea superfamily, which is composed of several families, such as Colubridae, Viperidae, Lamprophiidae and Elapidae \[[@pntd.0007017.ref006], [@pntd.0007017.ref007]\]. The Elapidae family consists of 61 genera and includes 365 species \[[@pntd.0007017.ref008]\], which are distributed in the tropical and temperate regions of Africa, America, Asia and Australia. These snakes can live in terrestrial or aquatic environments and present variable diet, including small vertebrates, such as birds, rodents, reptiles and fishes or invertebrates \[[@pntd.0007017.ref009], [@pntd.0007017.ref010]\].

The venom of Elapidae is well known to contain powerful neurotoxins that play a role in the snake defense against predators and prey capture. These neurotoxins may also be responsible for some of the clinical manifestations observed in human envenomation, such as respiratory arrest \[[@pntd.0007017.ref011], [@pntd.0007017.ref012]\]. However, several studies have noted the presence of different components in these venoms, including phospholipases A~2~ (PLA~2~), hyaluronidases (HYA) \[[@pntd.0007017.ref013], [@pntd.0007017.ref014], [@pntd.0007017.ref015]\], metallo- (SVMP) and serine proteinases (SVSP) \[[@pntd.0007017.ref016], [@pntd.0007017.ref017], [@pntd.0007017.ref018]\], inhibitors \[[@pntd.0007017.ref019]\], peptides \[[@pntd.0007017.ref020]\] and cytotoxins \[[@pntd.0007017.ref021], [@pntd.0007017.ref022]\]. All of these components may have cytotoxic \[[@pntd.0007017.ref014], [@pntd.0007017.ref023], [@pntd.0007017.ref024]\], hemorrhagic, anticoagulant \[[@pntd.0007017.ref025]\], pro-inflammatory \[[@pntd.0007017.ref026], [@pntd.0007017.ref027]\] or immunogenic \[[@pntd.0007017.ref028]\] properties.

The genus Naja presents specimens that cause a large and serious number of accidents \[[@pntd.0007017.ref003], [@pntd.0007017.ref008], [@pntd.0007017.ref023], [@pntd.0007017.ref029]\]. One dangerous representative of this genus is *Naja annulifera*, which is popularly called the Banded or Snouted Cobra \[[@pntd.0007017.ref030], [@pntd.0007017.ref031]\]. It is found in Sub-Saharan Africa countries, including Zambia, Malawi, Mozambique, Swaziland, Zimbabwe, Botswana and South Africa, in savannah grasslands, deserts, and rocky areas and near human habitations. This ranging of habits is associated to its broad diet, once it feeds on frogs, lizards, birds and it eggs, snakes and rats.

Accidents involving *N*. *annulifera* are considered severe. The envenomed individuals experience swelling, pain and local burning at the site of the bite, followed by pain throughout their entire body. Beside these clinical findings, affected individuals can present with dizziness and palpebral ptosis. Some can progress to respiratory arrest and, without a specific treatment, death. The treatment for envenomated individuals is serum therapy and in respiratory arrest cases, mechanical ventilation. Some studies have also reported that envenomed individuals in South Africa may develop necrosis at the site of the bite as well as hematologic disturbances \[[@pntd.0007017.ref023], [@pntd.0007017.ref031], [@pntd.0007017.ref032], [@pntd.0007017.ref033]\].

Veterinary epidemiologic data demonstrated that approximately 60% of dogs poisoned by snakebites in South Africa were bitten by *N*. *annulifera*. These dogs presented with various clinical findings, including hematologic alterations, such as leukocytosis and thrombocytopenia \[[@pntd.0007017.ref034]\], increased plasma levels of Cardiac Troponin I and C Reactive Protein (CRP) \[[@pntd.0007017.ref035]\] and disturbances in the coagulation system \[[@pntd.0007017.ref036]\].

Information about the components of *N*. *annulifera* venom is scarce. Some authors have noted the presence of several cyto/cardiotoxins and neurotoxins \[[@pntd.0007017.ref037], [@pntd.0007017.ref038], [@pntd.0007017.ref039], [@pntd.0007017.ref040], [@pntd.0007017.ref041], [@pntd.0007017.ref042]\]. Despite its medical importance, epidemiologic, clinical and experimental studies of *N*. *annulifera* venom are limited and the mechanisms by which it causes toxicity remains poorly understood. The goal of the present study was therefore to describe the components of *N*. *annulifera* venom and its toxic activities, utilizing *in vitro* and *in vivo* models to better understand the pathology of envenomation by this snake.

Methods {#sec005}
=======

Reagents {#sec006}
--------

Bovine serum albumin (BSA), Concanavalin A from *Canavalia ensiforms* (ConA), Wheat Germ Agglutinin from *Triticutun vulgaris* (WGA), Tween 20, Triton X-100, 3'3'-Diaminobenzidine (DAB), Hyaluronic Acid, anti-mouse IgG horseradish labeled with Peroxidase (IgG-HRPO), Ortho-phenylenediamine (OPD), cetyltrimethylammonium bromide (CTAB), Gelatin, Comassie Brilliant Blue R-250, Human Fibrinogen (Fb), Human Thrombin, 1,10 Phenantroline (1,10 Phe), Phenylmethasulfonyl Fluoride (PMSF), Dimethyl Sulfoxide (DMSO), Cromolyn, Dexamethasone, Trypsin, Solid Phase Extraction Disks (SDB-XC membranes), Hepes, urea, iodoacetamide and trifluoroacetic acid (TFA) were purchased from Sigma-Aldrich (Missouri, USA). The Bicinchoninic Acid (BCA) Protein Assay Kit was purchased from Pierce Biotechnology, Inc. (Wisconsin, USA). SDS-PAGE (Amersham ECL Gel 8--16%, 10 wells) gels were obtained from GE Healthcare Life Sciences (Uppsala, Sweden). Dithiothreitol (DTT) was from Calbiochem (Darmstadt, Germany). The nitrocellulose membrane and EnzChek Phospholipase A2 Assay Kit were purchased from Thermo Fisher Scientific (Massachusetts, USA). Aluminum Hydroxide (Al(OH)~3~) was purchased from Prati Donaduzzi (Sao Paulo, Brazil). Anti-mouse IgG labeled with alkaline phosphatase (IgG-AP), Nitroblue Tetrazolium chloride (NBT), 5-bromo-4-chloro-3-indolyl-phosphatase (BCIP) and CytoTox 96 Non-Radioactive Cytotoxicity Assay Kit were obtained from Promega Corp. (Madison, Wisconsin, USA). ELISA plates were purchased from Costar Corning, Inc. (New York, USA). Calcium chloride, Cephalin and Thromboplastin were obtained from Stago (Saint-Quen-I'Aumône, France). Indomethacin, MK-886 (Sodium Salt) and WEB-2086 were purchased from Cayman Chemical (Michigan, USA). The BD Cytometric Bead Array (CBA) Mouse Inflammation and Mouse IL-1β ELISA kits were obtained from BD Biosciences (New Jersey, USA). The mouse IL-17 DuoSet3.2.4.3 ELISA kit was obtained from R&D Systems (Minnesota, USA). The Panótico Rápido kit was purchased from Laborclin (Parana, Brazil). The HaCat human keratinocyte lineage was obtained from the Rio de Janeiro Cell Bank (Rio de Janeiro, Brazil). Dulbecco\'s Modified Medium Eagle---Gibco (DMEM) medium, penicillin and streptomycin were purchased from Invitrogen Corp. (California, USA). Fetal Bovine Serum was obtained from Cultilab (São Paulo, Brazil). 3-(4,5-dimethylthiazol-2-yl)2,5-di-phenyltetrazolium bromide (MTT) was obtained from Merk (Darmstadt, Germany). Frits for SPE cartridges were obtained from Agilent (California, USA) 10 μm Jupiter C-18 beads were purchased from Phenomenex (Torrance, USA). 3 μm ReproSil-Pur C-18 beads were obtained from Dr. Maisch (Ammerbuch, Germany). 75 μm I.D. or 100 μm I.D. x 360 μm O.D. polyimide coated capillary tubing were purchased from Molex (Lisle, USA).

Venoms {#sec007}
------

*N*. *annulifera* venom (South Africa specimens) was purchased from Latoxan Natural Active Ingredients (Valence, France). The lyophilized venom was reconstituted in sterile saline solution at 5 mg/mL. The protein content was assessed with the BCA Protein Assay Kit according to the manufacturer's recommendations. The samples were aliquoted and stored at -80°C until use. *Bothrops jararaca*, *Crotalus durissus terrificus* and *Tityus serrulatus* venoms were supplied by Butantan Institute, SP, Brazil, and their use was approved by the Brazilian Institute of Environment and Renewable Resources (IBAMA), an enforcement agency of the Brazilian Ministry of the Environment (protocol number: 010035/2015-0), and by SisGen (Sistema Nacional do Patrimônio Genético e do Conhecimento Tradicional Associado (protocol numbers AD50761 and AEE9AEA).

Ethics statement {#sec008}
----------------

High~III~ (H~III~) female mice weighing 18--22 g were obtained from the Immunogenetics laboratory, while Balb/c male mice weighing 18--22 g were obtained from the Center for Animal Breeding, both from Butantan Institute. All procedures involving animals were in accordance with the ethical principles for animal research adopted by the Brazilian Society of Animal Science and the National Brazilian Legislation n°.11.794/08. The protocols used in the present study were approved by the Institutional Animal Care and Use Committee of the Butantan Institute (protocols approved n° 01092/13 and 01262/14).

Experiments using samples obtained from humans were previously approved by the Human Research Ethics Committee of the Municipal Health Secretary of São Paulo. Human blood samples were obtained from healthy donors who knew of the purposes of this study and signed the corresponding informed consent form (protocol approved n° 974.312).

Characterization of the components of *N*. *annulifera* venom {#sec009}
-------------------------------------------------------------

### Electrophoresis and lectin Western blot {#sec010}

Samples of *N*. *annulifera* venom (15 μg) were separated by SDS-PAGE on 8--16% or 12% gels \[[@pntd.0007017.ref043]\], under reducing or non-reducing conditions, and were silver stained \[[@pntd.0007017.ref044]\] or blotted on nitrocellulose membranes \[[@pntd.0007017.ref045]\]. After the transfer, the membranes were blocked with 5% BSA in Phosphate Buffered Saline (PBS) (8.1 mM sodium phosphate, 1.5 mM potassium phosphate, 137 mM sodium chloride and 2.7 potassium chloride, p.H. 7.2) and then incubated with peroxidase labeled lectins, ConA (1:1000 dilution) or WGA (1:2000 dilution) to detect residues of Mannose and N-acetylglucosamine \[[@pntd.0007017.ref046]\]. Glycosylated proteins were detected using a solution that contained 0.1% hydrogen peroxide plus 0.5 mg/mL DAB.

### Mass spectrometric protein identification {#sec011}

For the proteomic analysis, *N*. *annulifera* venom was submitted to trypsin digestion as described by Kinter and Sherman \[[@pntd.0007017.ref047]\]. Briefly, 200 μg venom (three replicates) were denatured with 6 M urea in 100 mM Tris-HCl, pH 8, and reduced with dithiothreitol (DTT) 10 mM for 1 h at room temperature. Cysteine carbamidomethylation was performed by incubation with iodoacetamide 40 mM for 1 h at room temperature, followed by addition of DTT 40 mM to consume excess of alkylating agent. Protein samples were diluted with water until the concentration of urea decreased to about 0.7 M and trypsin was added using an enzyme: substrate ratio of 1:50 (w/w) at 37°C for 18 h. The reaction was stopped with 20% TFA until pH 3 and desalting was carried out by loading individual samples to p-1000 StageTip SDB-XC \[[@pntd.0007017.ref048]\]. After drying using a vacuum centrifuge, peptide mixtures were dissolved in 100 μL of 0.1% formic acid (solution A) and peptide concentration was estimated. For that, a peptide standard curve was prepared using a mixture of trypsin-digested bovine serum albumin (MassPREP BSA Digestion Standard; Waters) ranging from 0.2 to 1.2 μg/μL (in solution A). The absorbance was measured at 214 nm using a NanoDrop spectrophotometer (Thermo Scientific), and peptide sample concentration was determined using the standard curve. For analysis, each peptide sample (5 μg) was automatically injected using an EASY Nano LCII system (Thermo Scientific) into a 5 cm of 10 μm Jupiter C-18 trap column (100 μm I.D. × 360 μm O.D.) coupled to an LTQ-Orbitrap Velos mass spectrometer (Thermo Scientific). Chromatographic separation of tryptic peptides was performed on a 15-cm long column (75 μm I.D. x 360 μm O.D.) packed in-house with 3 μm ReproSil-Pur C-18 beads (Dr. Maisch, Germany). Peptides were eluted with a linear gradient of acetonitrile in 0.1% formic acid (solution B) at 200 nL/min: the linear step used for the elution was 5--35% in 75 min. Spray voltage was set at 2.2 kV and the mass spectrometer was operated in data dependent mode, in which one full MS scan was acquired in the m/z range of 300--1,600 followed by MS/MS acquisition using collision induced dissociation of the ten most intense ions from the MS scan. MS spectra were acquired in the Orbitrap analyzer at 30,000 resolution (at 400 m/z) whereas the MS/MS scans were acquired in the linear ion trap. The minimum signal threshold to trigger fragmentation event, isolation window, activation time and normalized collision energy were set to, respectively, 1,000 cps, 2 m/z, 10 ms and 35%. A dynamic peak exclusion (list size of 500) was applied to avoid the same m/z of being selected for the next 20 seconds. Two independent LC-MS/MS runs were performed for each sample.

### Database search {#sec012}

Protein identification was performed using the MaxQuant software suite (v 1.5.3.12) \[[@pntd.0007017.ref049]\] using the theoretical trypsin fragments produced from the database restricted to the taxonomy "Serpentes" (Uniprot release September 14, 2016; 63,114 sequences). The database search considered the precursor mass tolerance of 20 ppm, in the first search, and the nonlinear mass recalibration was made in the masses of first pass identifications. The second search considered the mass tolerance of 4.5 ppm and tolerance for fragments was set to 0.5 Da. The following search parameters were used: iodoacetamide derivatives of cysteine were considered as fixed modification, oxidation of methionine was specified as variable modification, and up to two missed cleavages by trypsin were accepted. Assignments for peptides and proteins were accepted at a false discovery rate \< 1%. For the identification, only proteins identified in at least two experimental replicates, with at least 1 unique peptide and posterior error probability ≤ 0.01 were accepted. "Match between runs" feature was enabled. For each protein group in the MaxQuant's 'proteinGroups.txt' file, the first protein entry was selected as representative. The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium ([http://proteomecentral.proteomexchange.org](http://proteomecentral.proteomexchange.org/)), via the PRIDE partner repository \[[@pntd.0007017.ref050]\], with the dataset identifier: PXD010962 (Username: <reviewer27828@ebi.ac.uk>; Password: BNxFCLRG).

Toxic-Enzymatic properties of the venom {#sec013}
---------------------------------------

### Gelatinolytic activity {#sec014}

The gelatinolytic activity of the *N*. *annulifera* snake venom was evaluated with zymography using gelatin as the substrate \[[@pntd.0007017.ref051]\]. Samples of the venom (30 μg), prepared under non-reducing conditions, were separated via 10% SDS-PAGE with 1 mg/ml gelatin. The gels were washed for 2 hours at room temperature in 2.5% Triton X-100 solution and incubated overnight at 37°C in substrate buffer (50 mM Tris-HCl, 200 mM NaCl, 10 mM CaCl~2~, 0.05% Brij-35, p.H. 8.3). After this period, the gels were stained with Coomassie Brilliant Blue solution (40% methanol, 10% acetic acid and 0.1% Coomassie Brilliant Blue).

### Fibrinogen cleavage {#sec015}

Human fibrinogen samples (30 μg) were incubated with 5 μg of *N*. *annulifera* venom or saline for 1 hour at 37°C under constant agitation. In parallel, venom samples were pre-incubated with 1.10 Phe (10 mM) or PMSF (10 mM) at room temperature for 30 minutes. After incubation, the mixtures were submitted to SDS-PAGE using a 8--16% gradient gel under reducing conditions and stained with Coomassie Brilliant Blue solution. The positive control of the reaction was human Thrombin (1U).

### Hyaluronidase activity {#sec016}

Hyaluronidase activity was analyzed according to the methodology described by Purkrittayakamee et al. \[[@pntd.0007017.ref052]\] with slight modifications. Briefly, samples of *N*. *annulifera* venom (20 μg) were incubated with a mixture that contained hyaluronic acid (1 mg/mL) (100 μL) and acetate buffer (200 mM sodium acetate and 0.15 M of NaCl, p.H. 6.0) (400 μL) at 37°C for 15 minutes. After incubation, the reactions were stopped with 1 mL of CTAB (2.5% CTAB and 2% NaOH). The absorbances were measured at λ405 nm in a spectrophotometer (Multiskan EX, Labsystems, Finland) against a blank that contained hyaluronic acid, acetate buffer and CTAB. The results are expressed as units of turbidity reduction (UTR) *per* mg of venom. *T*. *serrulatus* scorpion venom (20 μg) was used as a positive control.

### PLA~2~ activity {#sec017}

PLA~2~ activity was evaluated using the EnzChek^TM^ Phospholipase A2 Assay Kit according to the manufacturer's recommendations. Briefly, samples of *N*. *annulifera* venom (0.5 μg) was incubated with a phospholipid mix that contained 10 mM Dioleoylphosphatidylcholine and 10 mM Dioleoylphosphatidylglycerol in 96-well microtiter plates. Increased fluorescence was evaluated using a spectrometer FLUOstar Omega (BMG Labtech, Ortenberg, Germany) at λ~EM~ 460 and λ~EX~ 515 nm and 37°C for 10 minutes. Specific activity was expressed as Units of Fluorescence (UF) *per* minute *per* microgram of venom. *C*. *d*. *terrificus* (0.5 μg) venom was used as positive control.

### Cytotoxic activity {#sec018}

The HaCat human keratinocyte cell lineage was cultured in DMEM supplemented with 10% fetal bovine serum and 1% penicillin-streptomycin at 37°C and 5% CO~2~. The action of *N*. *annulifera* venom on the viability of human keratinocytes was evaluated using the MTT (3- (4,5-dimethylthiazol-2-yl) -2,5-diphenyltetrazolium bromide) method \[[@pntd.0007017.ref053]\] with minor modifications. Keratinocytes (5×10^4^ cells/well) were grown in 96-well plates that contained supplemented DMEM medium and were then maintained for 24 hours in DMEM medium without SFB. After this period, cells were incubated for 72 hours in increasing venom concentrations at 37°C and 5% CO~2~. The supernatant from the wells was aspirated and 60 μl of the MTT solution (0.83 μg/μL) in incomplete DMEM medium was added to the wells. The plates were then incubated for 30 minutes at 37° C and 5% CO~2~. Thereafter, the supernatant was aspirated, 100 μL/well of DMSO was added, and the plates were allowed to stand at room temperature for five minutes. The spectrophotometric analysis of the reactions (Multiskan-EX, Labsystems, Helsinki, Finland) was performed at λ 540 nm. Cell viability was calculated as: \[O.D. experimental sample ~(540nm)~\*100\]/\[O.D. control sample~(540nm)~\]. The results are expressed as cell viability (%).

Additionally, the action of *N*. *annulifera* venom on the viability of human keratinocytes was evaluated by Lactate Dehydrogenase (LDH) release assay. Supernatants of keratinocyte cultures, treated for 72 hours with increasing venom concentrations, were centrifuged at 405× *g* for 10 min, and tested for the presence of LDH, using the CytoTox 96 Non-Radioactive Cytotoxicity Assay Kit, according to the manufacturer\'s instructions.

The impact of venom on hemostatic parameters {#sec019}
--------------------------------------------

Blood samples from healthy donors were placed into tubes containing sodium citrate (3.2%) and centrifuged at 260× *g* at room temperature to obtain platelet-poor plasma (PPP). The PPP samples were aliquoted and stored at -20°C until their use.

### Activated Partial Thromboplastin Time (APTT) {#sec020}

PPP samples (50 μL) were treated with saline or increasing concentrations of venom and incubated for 3 minutes at 37°C with 50 μL of Cephalin. PPP was then recalcified with CaCl~2~ (0.025 M), and the coagulation time was measured over 240 seconds in a Stago Start System (Asnières-sur-Seine, France). The results are expressed in seconds and *R-time*, which was obtained from the experimental sample/control sample. Disorders in coagulation time were considered significant when the *R-time* was over 1.3 \[[@pntd.0007017.ref054]\].

### Prothrombin Time (PT) {#sec021}

PPP samples (50 μL) were treated with saline or increasing concentrations of venom and incubated for 1 minute at 37°C. PPP was then incubated with CaCl~2~ (0.025 M) that contained thromboplastin (100 μL), and the coagulation time was followed for 60 seconds using the Stago Start System (Asnières-sur-Seine, France). The results are expressed in seconds and *R-time*, which was obtained from the experimental sample/control sample. Abnormalities in coagulation time were considered significant when the *R-time* was over 1.3 \[[@pntd.0007017.ref054]\].

*In vivo* assays {#sec022}
----------------

### Lethal Activity of the venom (LD~50~) {#sec023}

Balb/c mice groups (n = 6) were intraperitoneally (i.p) inoculated with increasing concentrations of venom (20, 40, 60, 80, 100 and 120 μg) \[[@pntd.0007017.ref055]\] or sterile saline. After inoculation, animals were monitored for 72 hours and LD~50~ was calculated using the Probit transformation \[[@pntd.0007017.ref056]\]. The results are expressed as μg of venom *per* mouse.

### Local reactions: Edematogenic activity and pharmacological modulation {#sec024}

The venom edematogenic activity was assessed via the method previously published by Yamakawa et al. \[[@pntd.0007017.ref057]\] with some modifications. Balb/c mice (n = 6) were inoculated with 10 μg of *N*. *annulifera* venom at a volume of 50 μL (sterile saline) in the subcutaneous (s.c) tissue of the plantar region of the animal's left hindpaw. The contralateral hindpaw (control) was inoculated with 50 μL of sterile saline. To assess edematogenic activity, the thickness of the hindpaw was evaluated with a caliper rule (Mitutoyo, Suzano-SP, Brazil; sensibility of 0.01 mm) at different time points before (T0) and over the 24 h, following either venom or saline inoculation (Te). Increases in paw volume are expressed in percentage form (%), calculated with the following formula: (Te-T0)/T0\*100.

To evaluate the contribution of mast cells and different lipid mediators to the hindpaw edema induced by *N*. *annulifera* venom, mice (n = 6 *per* drug) were pretreated with different anti-inflammatory compounds: a) Sodium Cromoglycate, a mast cell degranulation inhibitor (10 mg/kg), administered i.p. for 3 days before edema induction \[[@pntd.0007017.ref058]\]; b) dexamethasone, an indirect cPLA~2~ inhibitor, was given to mice (2 mg/kg) i.p. 2 h before venom inoculation \[[@pntd.0007017.ref059]\]; c) the non-selective cyclooxygenase inhibitor Indomethacin, was administered (10 mg/kg) i.p. 30 minutes \[[@pntd.0007017.ref060]\] before venom; d) MK-886, a 5-lipoxigenase-activating protein inhibitor, was administered (5 mg/kg) i.p. 30 minutes \[[@pntd.0007017.ref061]\] before edema induction; and e) WEB-2086, a Platelet Activating Factor Receptor antagonist, was administered (5 mg/kg) s.c. 1 hour before venom administration \[[@pntd.0007017.ref062], [@pntd.0007017.ref063]\]. Dexamethasone and Cromolyn were diluted in saline, while Indomethacin, MK-886, WEB-2086 were diluted in DMSO. Following these pretreatments, edema was induced and monitored for 24 h.

### Systemic reactions {#sec025}

To analyze the possible systemic reactions induced by *N*. *annulifera* venom, two experimental groups were established. The first measured systemic alterations over time. LD~50~ assays were performed to define the sublethal dosing level that was able to induce the deleterious effects of the venom, including an increase in inflammatory parameters, but not kill the animals. LD~50~ values that varied between 50 and 75% were tested, and the selected dose for the inflammatory assays was 60% of LD~50~. Balb/c mice (n = 6) were then inoculated with 60% of LD~50~ or sterile saline i.p. and euthanized at different time points to obtain blood and collect the organs.

In another experimental set, it was assessed whether death promoted by venom was preceded by systemic reactions. Animal groups (n = 6) were inoculated with saline or 2 LD~50~ of *N*. *annulifera* venom i.p. Immediately after animals' death, their blood and organs were collected. Blood samples were obtained by cardiac puncture and were immediately incubated with EDTA (2.5 mg/mL). Aliquots of these samples were used to measure systemic leukocyte changes, while other blood samples were centrifuged at 2800× *g* at 4°C for 10 minutes to isolate plasma. Plasma samples were stored at -80°C and used to measure inflammatory mediators.

### Leukocyte alterations {#sec026}

To analyze changes in the total number of leukocytes, blood samples were diluted 1:10 in Turk's solution (0.1% crystal violet dye in 2% acetic acid), and the cells were counted in a Neubauer chamber. Blood samples were also submitted for blood smear and stained with a Fast Panoptic stain kit. Differential cell counts were performed by analyzing 100 cells that were identified as lymphocytes, neutrophils or monocytes based on morphologic criteria.

### Detection of inflammatory mediators {#sec027}

IL-6, TNF-α, MCP-1, IL-12, IFN-γ and IL-10 detection was performed using the BD Cytometric Bead Array (CBA) Mouse Inflammation Kit (BD Bioscience). IL-1β and IL-17 quantification was performed using the Mouse IL-1β ELISA (BD Bioscience) and Mouse IL-17 Duo3.2.43 ELISA (R&D Systems) kits, respectively. All assays were performed according to the manufacturer's instructions. The results are expressed as pg/mL.

### Histopathologic analysis {#sec028}

To analyze systemic histopathologic changes, Balb/c mice (n = 6) were inoculated i.p. with a sublethal dose or 2DL~50~ of *N*. *annulifera* venom. After euthanasia or death, animals were exsanguinated, and their brains, lungs, hearts, kidneys, spleens and livers were collected. To analyze local histopathological changes, Balb/c mice (n = 3) were injected subcutaneously with 10 μg of *N*. *annulifera* venom at a volume of 50 μL (sterile saline) in the plantar region of their left hindpaws. The contralateral hindpaws (control) were inoculated with 50 μL of sterile saline. Animals were euthanized at different time points (0, 20, 60, 240 and 1440 minutes) and had their hindpaws removed. The hindpaws and organs were fixed in a 10% formaldehyde solution for 24 hours, submitted for routine histology and stained with hematoxylin and eosin (HE). All samples were analyzed with a light microscope and were examined for the presence of necrosis, edema, inflammatory infiltrates or hemorrhagic foci.

Experimental antivenom production {#sec029}
---------------------------------

### Immunogenicity {#sec030}

H~III~ mice (n = 12) were immunized subcutaneously with 10 μg of *N*. *annulifera* venom diluted 1:25 on Al(OH)~3~ to achieve a final volume of 200 μL. These animals received three booster doses (5 μg) at 20-day intervals. Control animals were inoculated with sterile saline. Bleeding was performed 10 days after each venom inoculation. Blood was allowed to clot at room temperature for 15 minutes and was then left at 4° C for 6 hours. After centrifugation at 252× *g* and 4° C, the sera were collected and immediately frozen at -20° C.

### Sera antibody titers {#sec031}

To evaluate the sera antibody titers of immunized animals, ELISA plates (Costar) were coated with 100 μL of *N*. *annulifera* venom (10 μg/mL) and incubated overnight at 4° C. The plates were then blocked with 5% BSA in PBS for 2 hours at 37° C and incubated with crescent dilutions of non-immune or experimental sera samples for 1 hour at room temperature. After incubation, the plates were washed with PBS-Tween 20 0.05%, and incubated with the IgG-HRPO (1:5000 diluted) secondary antibody in 1% BSA/PBS for 1 hour at 37° C. The plates were then washed, and the reactions were developed with OPD substrate according to the manufacturer's instructions. The optical densities were obtained using spectrophotometry (Multiskan EX, Labsystems, Finland) at λ492 nm.

### Recognition of venom components using experimental antivenom {#sec032}

Samples of *N*. *annulifera* venom (15 μg) were separated using 8--16% gradient SDS-PAGE \[[@pntd.0007017.ref043]\] and blotted on nitrocellulose membranes \[[@pntd.0007017.ref045]\]. The membranes were blocked for 2 hours with 5% BSA in PBS, washed three times with PBS, incubated with normal or experimental sera pools, and diluted 1:5000 in 0.01% PBS/BSA for 1 hour at room temperature. After incubation, the membranes were washed with PBS-0.05% Tween 20, incubated with IgG-AP secondary antibodies, and diluted 1:5000 in 1% BSA/PBS for 1 hour at room temperature. After incubation, the membranes were washed three times in PBS-0.05% Tween 20. Antigenic reactivity was measured by the addition of NBT and BCIP substrates according to the manufacturer's recommendations.

### Serum neutralization of the venom's lethal activity {#sec033}

To determine the neutralizing potential of the experimental antivenom, samples of the venom, equivalent to 2LD~50~ (188.28 μg), were incubated with saline or crescent dilutions of the experimental serum for 30 minutes at 37° C. These mixtures were then i.p. administered to Balb/c mice (n = 6) (200 μL). Animals were observed for 72 hours and the death/survival ratio recorded. The neutralizing potential was calculated by Probit analysis and the results expressed as potency (mg of venom neutralized by mL of experimental serum) \[[@pntd.0007017.ref056]\].

Statistical analysis {#sec034}
--------------------

Statistical analysis was performed using one-way ANOVA followed by Tukey's Multiple comparison test, two-way ANOVA followed by a Bonferroni multiple comparison or *t-*tests. All statistical analyses were performed using Graphpad Prism 5 software (La Jolla, California, USA). Differences were considered significant when p ≤ 0.05.

Results {#sec035}
=======

*N*. *annulifera* venom composition {#sec036}
-----------------------------------

The analysis of the electrophoretic profile of *N*. *annulifera* venom using a 8--16% SDS-polyacrylamide gel, under non-reducing conditions, revealed protein bands with relative molecular masses between \~10 kDa and \~190 kDa. Under reducing conditions, the venom displayed a more simple profile, with main protein bands ranging from \~6 kDa to \~100 kDa ([Fig 1A](#pntd.0007017.g001){ref-type="fig"}), indicating that the venom contains protein in oligomeric state. To better characterize venom proteins, nitrocellulose membranes to which venom samples had been transferred were incubated with the ConA and WGA lectins, which recognize mannose \[[@pntd.0007017.ref064]\] and N-acetylglucosamine \[[@pntd.0007017.ref065]\] residues, respectively. [Fig 1B](#pntd.0007017.g001){ref-type="fig"} shows three protein bands (\~70, \~86 and \~103 kDa) that interacted with WGA indicating the presence of N-acetylglucosamine. Moreover, three bands that interacted with ConA (\~63, \~81 and \~170 kDa) indicated that these proteins contain mannose residues in their carbohydrate moieties ([Fig 1C](#pntd.0007017.g001){ref-type="fig"}).

![Characterization of the venom components.\
\[A\] SDS-polyacrilamide gel electrophoresis of *N*. *annulifera* venom. Venom samples (15 μg) were separated using a 8--16% SDS-polyacrylamide gel under non-reducing \[NR\] or reducing \[R\] conditions and silver stained. Analysis of the presence of \[B\] N-acetylglucosamine and \[C\] Mannan residues in the venom. Samples of *N*. *annulifera* venom (15 μg) were separated via SDS-PAGE and blotted onto a nitrocellulose membrane. The membranes were then incubated with the lectins WGA \[B\] or ConA \[C\], and the reactions were revealed with DAB plus H~2~O~2~.](pntd.0007017.g001){#pntd.0007017.g001}

The venom proteomic analysis using in-solution trypsin digestion and LC-MS/MS resulted in the identification of 79 proteins, including 24 types of venom components with or without enzymatic function, and six proteins of unknown function. Despite the variety of proteins identified in the venom, it is dominated by the presence of 3FTx (27 proteins) ([Table 1](#pntd.0007017.t001){ref-type="table"}; [S1](#pntd.0007017.s001){ref-type="supplementary-material"} and [S2](#pntd.0007017.s002){ref-type="supplementary-material"} Tables; [S1 Spectra](#pntd.0007017.s003){ref-type="supplementary-material"}). Other protein classes identified in the venom include cysteine-rich secretory protein (CRISP), Kunitz-type protease inhibitor, snake venom metalloproteinase (SVMP), snake venom serine proteinase (SVSP), phospholipase A2 (PLA~2~), hyaluronidase (glycosyl hydrolase 56 family) and Cobra Venom Factor (venom complement C3 homolog).

10.1371/journal.pntd.0007017.t001

###### List of proteins identified in *Naja annulifera* venom by in-solution trypsin digestion and LC-MS/MS analysis[\*](#t001fn001){ref-type="table-fn"}.

![](pntd.0007017.t001){#pntd.0007017.t001g}

  Protein family                                   Protein ID[\*\*](#t001fn002){ref-type="table-fn"}            Protein                                                   \# Peptides
  ------------------------------------------------ ------------------------------------------------------------ --------------------------------------------------------- -------------
  Snake three-finger toxin family                  P01454                                                       Cytotoxin 9                                               14
  P62394                                           Cytotoxin 11                                                 6                                                         
  P01421                                           Short neurotoxin 4                                           10                                                        
  P68419                                           Short neurotoxin 1                                           12                                                        
  P01456                                           Cytotoxin 1                                                  13                                                        
  Q9W717                                           Neurotoxin-like protein NTL2                                 2                                                         
  P01463                                           Cytotoxin 2                                                  7                                                         
  P01453                                           Cytotoxin 10                                                 10                                                        
  P29181                                           Weak neurotoxin 7                                            2                                                         
  P01401                                           Weak toxin CM-11                                             8                                                         
  P01399                                           Weak toxin CM-13b                                            4                                                         
  P01462                                           Cytotoxin 2                                                  11                                                        
  P81782                                           Bucandin                                                     3                                                         
  P01400                                           Weak toxin S4C11                                             6                                                         
  P25674                                           Long neurotoxin 1                                            7                                                         
  P25678                                           Weak toxin CM-2a                                             3                                                         
  P01457                                           Cytotoxin 5                                                  6                                                         
  Q9W6W6                                           Cytotoxin 10                                                 5                                                         
  P01422                                           Short neurotoxin 2                                           7                                                         
  P82462                                           Muscarinic toxin-like protein 1                              2                                                         
  R4FK68                                           3FTx-Pse-105                                                 1                                                         
  P01461                                           Cytotoxin 4                                                  7                                                         
  R4G7H8                                           3FTx-Fur-10                                                  1                                                         
  P01464                                           Cytotoxin 5                                                  6                                                         
  P01388                                           Long neurotoxin 2                                            3                                                         
  P01389                                           Long neurotoxin 1                                            5                                                         
  P01426                                           Short neurotoxin 1                                           5                                                         
  CRISP family                                     Q7T1K6                                                       Cysteine-rich venom protein natrin-1                      6
  P84808                                           Cysteine-rich venom protein kaouthin-2                       5                                                         
  P0DL15                                           Cysteine-rich venom protein annuliferin-b (Fragment)         5                                                         
  P84807                                           Cysteine-rich venom protein 25-A (Fragment)                  1                                                         
  Q8JI38                                           Cysteine-rich venom protein latisemin                        2                                                         
  F2Q6F2                                           Cysteine-rich seceretory protein Dr-CRPK                     2                                                         
  C1JZW4                                           Opharin                                                      2                                                         
  Q7ZT98                                           Cysteine-rich venom protein ophanin                          5                                                         
  Phospholipase A2 family                          B2BRS4                                                       Truncated putative phospholipase A2                       1
  P25498                                           Acidic phospholipase A2 E                                    1                                                         
  Q92085                                           Neutral phospholipase A2 B                                   1                                                         
  P00605                                           Phospholipase A2 basic                                       2                                                         
  P00600                                           Acidic phospholipase A2 DE-II                                4                                                         
  SVMP family                                      D6PXE8                                                       Zinc metalloproteinase-disintegrin-like atrase-B          5
  D5LMJ3                                           Zinc metalloproteinase-disintegrin-like atrase-A             7                                                         
  Q10749                                           Snake venom metalloproteinase-disintegrin-like mocarhagin    6                                                         
  P82942                                           Hemorrhagic metalloproteinase-disintegrin-like kaouthiagin   4                                                         
  D3TTC2                                           Zinc metalloproteinase-disintegrin-like atragin              6                                                         
  Type-B carboxylesterase/lipase family            A0A098LYB5                                                   Carboxylic ester hydrolase                                5
  R4FKE6                                           Carboxylic ester hydrolase (Fragment)                        4                                                         
  Q92035                                           Acetylcholinesterase                                         3                                                         
  A0A098LY86                                       Carboxylic ester hydrolase (Fragment)                        2                                                         
  Phosphodiesterase family                         A0A2D0TC04                                                   Snake venom phosphodiesterase (PDE)                       14
  A0A0F7YYZ8                                       Phosphodiesterase                                            9                                                         
  Lectin family                                    U3FVL3                                                       Vesicular integral-membrane protein VIP36                 1
  R4G314                                           LP-Pse-6                                                     1                                                         
  Flavin monoamine oxidase family                  A0A2R4N4Q6                                                   Amine oxidase (Fragment)                                  14
  R4FID0                                           Amine oxidase                                                8                                                         
  NGF family                                       P61899                                                       Venom nerve growth factor                                 7
  Q5YF89                                           Venom nerve growth factor 2                                  4                                                         
  Ohanin/vesprin family                            P82885                                                       Thaicobrin                                                6
  A0A182C6D0                                       Ohanin                                                       4                                                         
  5\'-nucleotidase family                          U3FYP9                                                       Ecto-5-nucleotidase 1c                                    13
  Ankyrin repeat                                   V8NWT6                                                       Ankyrin repeat domain-containing protein 34B (Fragment)   1
  Carbohydrate/starch-binding module (family 21)   V8N6R7                                                       Protein phosphatase 1 regulatory subunit 3A (Fragment)    1
  DEATH domain, DD                                 V8P0T5                                                       Tumor necrosis factor receptor superfamily member 11B     3
  Endonuclease family                              V8N4Y2                                                       Endonuclease domain-containing 1 protein                  5
  Glutathione peroxidase family                    V8P395                                                       Glutathione peroxidase (Fragment)                         10
  Glycosyl hydrolase 56 family (hyaluronidase)     U3FYQ4                                                       Hyaluronidase                                             3
  LDH/MDH superfamily                              V8P6K5                                                       L-lactate dehydrogenase                                   1
  Pyruvate kinase family                           V8P2C8                                                       Pyruvate kinase                                           1
  SVSP family                                      A8QL57                                                       Snake venom serine protease BmSP (Fragment)               2
  Thiolase family                                  V8NMW3                                                       Non-specific lipid-transfer protein                       1
  Tudor domain                                     V8NEV9                                                       Tudor domain-containing protein 6 (Fragment)              1
  Venom complement C3 homolog family               Q91132                                                       Cobra venom factor                                        18
  Venom Kunitz-type family                         P00986                                                       Kunitz-type serine protease inhibitor 2                   5
  Unknown                                          A0A2D4GN98                                                   Uncharacterized protein (Fragment)                        1
  V8NUN2                                           Transmembrane protein 14C                                    1                                                         
  A0A2D4JG71                                       Uncharacterized protein (Fragment)                           1                                                         
  A0A2D4KYJ8                                       Uncharacterized protein (Fragment)                           1                                                         
  A0A2D4H759                                       Uncharacterized protein (Fragment)                           1                                                         
  A0A2D4IS21                                       Uncharacterized protein (Fragment)                           1                                                         

\*Only proteins identified in at least two experimental replicates, with at least 1 unique peptide and posterior error probability ≤ 0.01 are listed.

\*\*The first protein entry was selected as a representative of each Protein Group as identified using the MaxQuant software package.

Toxic-Enzymatic properties of *N*. *annulifera* venom {#sec037}
-----------------------------------------------------

*N*. *annulifera* venom showed no proteolytic activity on zymography using gelatin as substrate. Under the same experimental conditions, proteins from the positive control of *B*. *jararaca* venom showed gelatinolytic activity, as demonstrated by clear regions in the gel (bands with molecular mass above 60 kDa) ([Fig 2A](#pntd.0007017.g002){ref-type="fig"}). However, when proteolytic activity on fibrinogen was assessed, it was observed that the venom contained proteinases that were able to cleave this protein at the alpha chain, generating a fragment with a molecular mass of \~ 40 kDa ([Fig 2B](#pntd.0007017.g002){ref-type="fig"}). In addition, when inhibitors were added to the reactions, cleavage was inhibited by 1, 10 Phe and PMSF, demonstrating the contributions of SVMP and SVSP to this hydrolysis ([Fig 2B](#pntd.0007017.g002){ref-type="fig"}).

![Toxic-enzyme properties of *N*. *annulifera* venom.\
\[A\] Zymography: Samples of *N*. *annulifera* venom (30 μg) were assessed via 10% SDS-PAGE in the presence of 1 mg/mL gelatin and then incubated with the substrate buffer. Gels were stained with *Comassie Brilliant Blue*. The venom of *B*. *jararaca* (10 μg) was used as a positive control. \[B\] Fb cleavage: Fb samples (30 μg) were incubated with *N*. *annulifera* venom (5 μg) with or without metallo- (10 mM) and serine proteinase (10 mM) inhibitors for 1 hour. Samples were then analyzed via SDS-PAGE (8--16% gradient gel) and stained with *Comassie Brilliant Blue*. \[C\] Hyaluronidase activity: samples of *N*. *annulifera* venom (20 μg) were incubated at 37°C for 15 minutes in a solution containing hyaluronic acid. After the incubation, the reactions were stopped with CTAB and the absorbances were measured at λ 405 nm with a spectrophotometer. As a positive control, *T*. *serrulatus* (20 μg) scorpion venom was used. The results are representative of three separate experiments and expressed as UTR/mg of venom ± SD. Statistical analysis was performed using the *t-test* (\*\*\* *p≤* 0.05). \[D\] PLA~2~ activity: Samples of *N*. *annulifera* venom (0.5 μg) were incubated at 37°C with a phospholipid mix that contained 10 mM phosphatidylcholine and 10 mM phosphatidylglycerol. Increased fluorescence was measured for 10 minutes. As a positive control, *C*. *d*. *terrificus* venom (0.5 μg) was used. The results are representative of three separate experiments and expressed as specific activity (UF *per* μg of venom *per* minute) ± SD. Statistical analysis was performed using *t-test* (\*\*\* *p≤* 0.05). \[E\] Cytotoxic activity: The HaCat human keratinocyte cell lineage was cultured in DMEM medium and incubated during 72 hours with increasing amounts of *N*. *annulifera* venom. The effect on cell viability was evaluated using the MTT method and by measuring LDH release from human keratinocytes exposed to the venom, using the CytoTox 96 Non-Radioactive Cytotoxicity Assay Kit. Statistical analysis was performed using One Way ANOVA (\*\*\* *p≤* 0.05) ± SD.](pntd.0007017.g002){#pntd.0007017.g002}

The hyaluronidase activity of *N*. *annulifera* snake venom was assessed via a turbidimetric assay, and the results are expressed in UTR. It was demonstrated that *N*. *annulifera* venom has a low hyaluronidase activity (UTR = 14.4) compared to the positive control *T*. *serrulatus* scorpion venom (UTR = 52.8) ([Fig 2C](#pntd.0007017.g002){ref-type="fig"}).

PLA~2~ activity was measured with a fluorimetric assay, and the results obtained are expressed as specific activity (SA: UF/min/μg venom). [Fig 2D](#pntd.0007017.g002){ref-type="fig"} shows that *N*. *annulifera* snake venom has significantly lower phospholipase activity (SA: 566.2) than the *C*. *d*. *terrificus* venom positive controls (SA: 3061.3).

Cytotoxic properties of the venom were evaluated by cell viability and LHD release assays. *N*. *annulifera* venom was able to reduce human keratinocyte viability in a dose-dependent manner but was not able to promote LDH release by the cells ([Fig 2E](#pntd.0007017.g002){ref-type="fig"}).

The impact of *N*. *annulifera* on hemostasis {#sec038}
---------------------------------------------

*N*. *annulifera* venom induced disturbances in the Activated Partial Thromboplastin Time in a dose dependent manner ([Table 2](#pntd.0007017.t002){ref-type="table"}). Platelet-poor plasma (PPP) samples were incoagulable when the highest venom concentrations were used (12.5 to 50 μg), while the coagulation time (seconds) was significantly prolonged at lower concentrations (2.5 to 6.25 μg) (*p≤* 0.05). Moreover, the *R-time* shows that the disturbances promoted by *N*. *annulifera* venom were severe, as they were much higher than normal. Prothrombin Time assays demonstrated that the venom led to a significant prolongation in the coagulation time of PPP at the highest venom concentrations, *i*.*e*., 25 and 50 μg. Besides that, both venom concentrations were able to cause a significant alteration in the *R-time* ([Table 2](#pntd.0007017.t002){ref-type="table"}).

10.1371/journal.pntd.0007017.t002

###### Alterations in aTTP and PT induced by *N*. *annulifera* venom.

![](pntd.0007017.t002){#pntd.0007017.t002g}

  Assay          C      2.5 μg       3.12 μg      6.25 μg      12.5 μg     25 μg       50 μg
  -------------- ------ ------------ ------------ ------------ ----------- ----------- ------------
  **aTTP**       38     78.4\*\*\*   92.8\*\*\*   98.9\*\*\*   -\*\*\*     -\*\*\*     -\*\*\*
  ***R-time***   1      2.1\*\*\*    2.3\*\*\*    2.3\*\*\*    6.3\*\*\*   6.3\*\*\*   6.3\*\*\*
  **PT**         15.5   15.5         15.5         15.5         15.3        18.3\*\*    33.6\*\*\*
  ***R-time***   1      1            1            1            1           1.33\*\*    2.2\*\*\*

aTTP: Activated Partial Thromboplastin Time; PT: Prothrombin Time; -: Incoagulable; C: Control (PPP samples treated with sterile saline); *R-time*: scale of abnormalities in coagulation time. Statistical analysis was performed using Two Way ANOVA (\*\* and \*\*\* *p≤* 0.05) ± SD.

Toxicity of *N*. *annulifera* venom in the murine model {#sec039}
-------------------------------------------------------

### Local reactions {#sec040}

To evaluate the edematogenic activity of *N*. *annulifera* venom, Balb/c mice were inoculated with 10 μg of venom into their left hind footpads, and their paws were measured at different time points. The venom was able to induce a significant rapid onset of edema, with its maximum peak (110.13% of increase on paw volume) reached 20 minutes after inoculation. It returned to basal level 24 hours after venom inoculation ([Fig 3A](#pntd.0007017.g003){ref-type="fig"}).

![Local alterations induced by *N*. *annulifera* venom.\
\[A\] Edema: samples of venom (10 μg/50 μL) or sterile saline were injected into the left or right hind footpad, respectively, of Balb/c mice (n = 6). Paw edema was assessed by measuring the paw thickness using a caliper rule before (T0) and after inoculation with venom or saline (Te). The increased paw volume was expressed as percentage (%) and was calculated with the following formula: (Te-T0)/T0\*100. Statistical analysis was performed using two-way ANOVA, followed by the Bonferroni multiple comparison test (\*\*\**p≤* 0.05) ± SD. \[B\] The effect of inhibitors on the paw edema induced by *N*. *annulifera* venom: groups of Balb/c mice (n = 6) were treated with different inhibitors before induction of edema with venom: Cromolyn, a mast cell degranulation inhibitor (10 mg/kg, three days consecutively before the edema, i.p. route); dexamethasone (Dexa), a cPLA~2~ inhibitor (2 mg/kg, 2 hours before the edema, i.p. route); indomethacin (Indo), a COX isoform inhibitor (10 mg/kg, 30 minutes before the edema, i.p. route); MK886, a 5-lipoxygenase-activating protein inhibitor (5 mg/kg, 30 minutes before the edema, i.p. route); and WEB2086, a PAFR antagonist (5 mg/kg, 1 hour before the edema, s.c. route). After treatment, edema was induced, and the paws were measured with a caliper rule at several time points. The increased paw volume was expressed as a percentage. Statistical analysis was performed using two-way ANOVA, followed by the Bonferroni multiple comparison test (\*\*\**p≤* 0.05) ± SD. \[C\] Histopathological changes promoted by *N*. *annulifera* venom: samples of *N*. *annulifera* venom (10 μg/50 μL) were injected into the left hind paw of Balb/c mice (n = 6). The contralateral paws were injected with sterile saline (50 μL) to serve as controls. The animals were euthanized at different time points, and their paws were removed and submitted for histopathological analysis. Control group \[Panel 1\]: epidermis (Ep), dermis (De), sweat glands (Sg) and muscle tissue (Mt). Experimental group \[Panel 2\]: arrows highlight vascular congestion and a perivascular inflammatory infiltrate; asterisks indicate areas of edema. The rectangle indicates areas of neutrophil infiltration \[Panel 3\] and myonecrosis \[Panels 4, 5\]. The arrow and asterisk in Panel 5 indicate dead and living cells, respectively. Scale = 10μm.](pntd.0007017.g003){#pntd.0007017.g003}

In addition to the evaluation of edematogenic activity, the contribution of mast cell and lipid mediators to edema development was also assessed. It was found that mast cell degranulation is important for the earliest development (10--30 minutes) of edema as treatment with Cromolyn, a mast cell degranulation inhibitor, was able to reduce swelling ([S1A Fig](#pntd.0007017.s004){ref-type="supplementary-material"}). Dexamethasone, a synthetic corticosteroid compound with a potent anti-inflammatory activity, had a strong effect on the paw edema induced by *N*. *annulifera* venom. It was able to decrease hindpaw thickness throughout the duration of edema, mainly during the early stages (10--30 minutes), suggesting that lipid mediators participate in the development of edema ([S1B Fig](#pntd.0007017.s004){ref-type="supplementary-material"}). Indomethacin, a non-selective COX inhibitor, was also able to reduce the degree of edema (10 to 120 minutes), suggesting that prostaglandins and thromboxanes may contribute to the local reaction to the venom. However, treatment with Indomethacin was not able to control swelling during the late phase (180 to 1440 minutes) ([S1C Fig](#pntd.0007017.s004){ref-type="supplementary-material"}). A similar effect was observed in animals treated with a FLAP inhibitor ([S1D Fig](#pntd.0007017.s004){ref-type="supplementary-material"}). The PAFR blocker WEB-2086 demonstrated inhibitory action only in the earliest phases of the edema (20--30 minutes) ([S1E Fig](#pntd.0007017.s004){ref-type="supplementary-material"}). Although all inhibitors showed different modulation profiles, they were able to significantly decrease the edema at its peak \[[Fig 3B](#pntd.0007017.g003){ref-type="fig"}\].

Histopathologic analyses showed that the venom promotes several changes, ranging from mild to intense, at all time periods \[[Fig 3C](#pntd.0007017.g003){ref-type="fig"}\]. After inoculation with the venom, it was observed that it promotes an acute inflammatory response at the inoculation site, with a disorganized dermal collagen matrix, subcutaneous edema, vascular congestion \[Panel 2\], mild erythrocyte extravasation and neutrophil migration to the dermis and muscle \[Panels 3, 4, 5\]. Myonecrosis was also observed \[Panels 4, 5\] along with polymorphonuclear cell infiltration. These alterations persisted for several hours. However, after 24 hours of inoculation, a decrease in the subcutaneous edema was observed, along with the absence of vascular congestion and few remaining neutrophils in the tissue. By contrast, an increased number of mononuclear cells and reorganization of the dermal collagen matrix was observed \[Panel 6\].

Lethal dose {#sec041}
-----------

LD~50~ was determined 72 hours after venom administration. Prior to their death, animals presented with several clinical findings of envenomation, including apathy, bending at the column, a rough hair coat, dyspnea and paralysis of their hind limbs. LD~50~ was calculated with a probit analysis with a 95% confidence interval and was found to be 94.14 μg (68.78--115.74).

Systemic reactions induced by *N*. *annulifera* venom {#sec042}
-----------------------------------------------------

The systemic reactions promoted by the venom were evaluated using two different experimental protocols. By injecting 60% (56.48 μg) (Sublethal dose) of LD~50~ of *N*. *annulifera* venom, it was observed that animals presented several clinical findings of envenomation, including apathy, bending at the column, a rough hair coat, dyspnea and difficulty walking. This dose was also able to cause alterations in some systemic parameters, such as a decrease of circulating lymphocytes \[[Fig 4A](#pntd.0007017.g004){ref-type="fig"}\] and an increased number of circulating neutrophils \[[Fig 4B](#pntd.0007017.g004){ref-type="fig"}\]. Nonetheless, this dose was not able to lead to changes in the total number of leukocytes and histological organs damage. However, a sublethal dose promoted an increase in the plasma levels of MCP-1 \[[Fig 4C](#pntd.0007017.g004){ref-type="fig"}\] and IL-6 \[[Fig 4D](#pntd.0007017.g004){ref-type="fig"}\]. These alterations persisted for several hours. However, 24 hours after experimental envenomation, all of these parameters returned to their normal values.

![Systemic changes promoted by *N*. *annulifera* venom.\
Balb/c mice were injected with either a \[A-D\] sublethal (56.48 μg) dose or \[E-I\] 2LD~50~ (188.28 μg) of venom intraperitoneally. After death, animals were exsanguinated and some organs were fixed in a 10% formaldehyde solution and submitted for histologic analysis. \[A, B, F\] Leukocyte alterations: blood samples obtained from the animals were diluted in Turk's solution or submitted for either a blood smear or Fast Panoptic stain to analyze total and differential leukocyte alterations. \[I\] Histopathological analysis: tissues were analyzed under a light microscope to detect histological alterations. Lungs: bronchiole (Br), blood vessel (Bv), alveoli (Al). Arrow and asterisk indicate vascular congestion and multifocal hemorrhage, respectively. Scale = 10μm. \[C, D, G, H\] Increased plasma levels of inflammatory mediators: plasma samples were submitted for CBA (BD Bioscience PharMingen, EUA) or ELISA (BD Bioscience PharMingen, EUA) (R&D Systems) according to the manufacturer's instructions. The results are expressed as pg/mL. Statistical analyses were performed using Graphpad Prism by means of a 2-way ANOVA followed by the Bonferroni multiple comparison test (\*\*\**p≤* 0.05) ± SD.](pntd.0007017.g004){#pntd.0007017.g004}

Injection of 2LD~50~ led to several clinical findings of envenomation, such as apathy, bending at the column, a rough hair coat, dyspnea, hind limb paralysis and death. In addition to these clinical findings, histopathologic alterations were observed in the lungs, among these, moderate vascular congestion and multiple hemorrhagic foci \[[Fig 4I](#pntd.0007017.g004){ref-type="fig"}\]. Furthermore, the animals demonstrated leukocytosis \[[Fig 4E](#pntd.0007017.g004){ref-type="fig"}\] characterized by neutrophilia and monocytosis \[[Fig 4F](#pntd.0007017.g004){ref-type="fig"}\], as well as increased plasma levels of MCP-1 \[[Fig 4G](#pntd.0007017.g004){ref-type="fig"}\] and IL-6 \[[Fig 4H](#pntd.0007017.g004){ref-type="fig"}\].

*N*. *annulifera* venom immunogenicity and antivenom production {#sec043}
---------------------------------------------------------------

The immunogenicity of *N*. *annulifera* snake venom was evaluated in H~III~ mice immunized with 10 μg of venom. The antibody titers were determined by ELISA. [Fig 5A](#pntd.0007017.g005){ref-type="fig"} presents the antibody response over time. *N*. *annulifera* venom is highly immunogenic, promoting the production of high antibody titers, already after the second immunization dose. The recognition profile of the venom proteins by the experimental *N*. *annulifera* mouse antiserum was determined by Western Blot. [Fig 5B](#pntd.0007017.g005){ref-type="fig"} shows that the experimental serum was able to recognize venom components, mainly proteins with Mr above 50 kDa. Moreover, as determined by Probit analysis, it was shown that this antivenom was able to neutralize the *N*. *annulifera* venom lethal activity with a high potency, *i*.*e*., 1 ml of antivenom was able to neutralize 4.5 mg of venom.

![*N*. *annulifera* venom immunogenicity, antivenom production and serum neutralization.\
\[A\] Antibody titers: ELISA plates were coated with 10 μg/mL venom (100 μL/well), incubated with increasing dilutions of non-immune (NI) or experimental sera obtained from H~III~ mice, and incubated with anti-mouse HRPO-conjugated IgG (1:5000). The reaction was performed with the addition of OPD and H~2~O~2~, and spectrophotometric readings were taken at λ 492 nm. \[B\] Western Blot: samples of the venom (15 μg) were separated via 8--16% gradient SDS-PAGE, blotted onto nitrocellulose membranes and incubated with the experimental serum diluted to 1:5,000 (α Na). The membranes were incubated with conjugated anti-mouse IgG-AP (1:7,500), and the reactions were started by adding NBT/BCIP.](pntd.0007017.g005){#pntd.0007017.g005}

Discussion {#sec044}
==========

In this study, we characterized some of the biochemical, toxic, immunogenic and physiopathologic properties of the venom from *N*. *annulifera*, which is a medically important snake related to accidental bites in the countries of Sub-Saharan Africa. The results show that *N*. *annulifera* venom contains several toxic components able to induce systemic inflammation, which may contribute to the pathology observed in envenomed individuals. Moreover, the venom is immunogenic, an important feature that must be considered during the production of a therapeutic anti-*N*. *annulifera* antivenom.

Electrophoretic analysis *of N*. *annulifera* venom showed that it contains several components, including low molecular mass proteins, which suggested the presence of neurotoxins \[[@pntd.0007017.ref018]\], among these, 3FTx \[[@pntd.0007017.ref014], [@pntd.0007017.ref015]\] and PLA~2~ \[[@pntd.0007017.ref016]\]. The presence of these components in the venom was confirmed by trypsin digestion of proteins and LC-MS/MS analysis. These components may be responsible for some of the clinical findings observed during envenomation, such as heart damage and systemic inflammation in dogs \[[@pntd.0007017.ref035]\], as well as respiratory arrest in humans \[[@pntd.0007017.ref023]\]. The data from this study corroborate the results of other studies, which showed the presence of these components in *N*. *annulifera* venom \[[@pntd.0007017.ref037], [@pntd.0007017.ref038], [@pntd.0007017.ref039], [@pntd.0007017.ref040], [@pntd.0007017.ref041], [@pntd.0007017.ref042]\]. Envenomed individuals from South Africa showed local dermonecrotic injury after a bite, which could be caused by the high content of cytotoxins, as shown in our LC-MS/MS analysis. In accordance with data from Panagides and colleagues \[[@pntd.0007017.ref066]\], here we also showed that *N*. *annulifera* venom could promote decrease in human epidermal cells viability, as evaluated by the MTT method. However, it was not possible to detect release of LDH by these cells, which possibly indicate that the keratinocyte membranes were not damaged and that the cell death promoted by *N*. *annulifera* could be due to apoptosis \[[@pntd.0007017.ref067]\] and not necrosis. Alternatively, it is possible to consider that *N*. *annulifera* venom contains components able to reduce mitochondrial activity, since MTT method evaluates cell viability as enzymatic conversion of the tetrazolium compound to water insoluble formazan crystals by dehydrogenases occurring in the mitochondria of living cells.

Western Blot lectin analysis demonstrated the presence of mannose and N-acetylglucosamine residues in *N*. *annulifera* venom proteins. These carbohydrate residues were found in the venom proteins of different genera of snakes \[[@pntd.0007017.ref046], [@pntd.0007017.ref068], [@pntd.0007017.ref069], [@pntd.0007017.ref070]\], including in important toxic components, such as SVSP and SVMP \[[@pntd.0007017.ref069], [@pntd.0007017.ref070]\]. Although we have not identified the families of these glycosylated components, it is possible that some of them are linked to SVMPs or SVSPs, as they have predicted molecular masses similar to some of the previously described glycosylated proteolytic enzymes from viperid venoms \[[@pntd.0007017.ref069], [@pntd.0007017.ref070]\]. Moreover, SVMPs and SVSPs were detected in *N*. *annulifera* venom by LC-MS/MS. Proteins containing these carbohydrate residues are also present in many pathogens, such as bacteria and fungi, and can be recognized by different immune cells and molecules, triggering inflammatory and immune responses \[[@pntd.0007017.ref071], [@pntd.0007017.ref072]\]. This recognition could contribute to the clinical manifestations observed during envenomation, such as the systemic inflammation observed in dogs \[[@pntd.0007017.ref035]\].

Functional biochemical assays were performed to confirm the presence of some of the toxic-enzymatic components found in the LC-MS/MS analysis. The presence of proteinases in animal venoms can contribute to different clinical manifestations during envenomation, such as inflammation, tissue damage, disturbances in coagulation and bleeding \[[@pntd.0007017.ref073]\]. In elapid venoms, proteolytic activity is usually low or nonexistent \[[@pntd.0007017.ref026], [@pntd.0007017.ref074], [@pntd.0007017.ref075]\]. In contrast to the data shown by Phillips et al. \[[@pntd.0007017.ref076]\], under the experimental conditions used in this paper, *N*. *annulifera* venom did not show any proteolytic activity on either gelatin. However, although detected at low abundance in the proteomic analysis, the venom contains SVMP and SVSP able to cleave the fibrinogen alpha chain, which suggests that these proteinases can contribute to the hemostatic alterations as observed in dogs envenomated by *N*. *annulifera* \[[@pntd.0007017.ref036]\].

Hyaluronic acid is cellular cement that, together with other components of the extracellular matrix, forms a protective gel that prevents the entry of foreign agents. A variety of animal venoms contain hyaluronidases, which cleave hyaluronic acid molecules to facilitate access of the venom from the tissue to the bloodstream. This enzyme is also called "spreading factor" \[[@pntd.0007017.ref077]\], and its action can promote local and systemic inflammation by increasing tissue permeability \[[@pntd.0007017.ref078]\]. Moreover, the products derived from hyaluronic acid cleavage, which can be recognized by immune receptors, such as TLR2 and 4, trigger the production of inflammatory mediators, such as cytokines and chemokines \[[@pntd.0007017.ref079]\]. *N*. *annulifera* venom showed evidence of hyaluronidase activity, but it was relatively low compared with other elapid venoms from the *Naja* \[[@pntd.0007017.ref074]\] and *Micrurus* \[[@pntd.0007017.ref016]\] genera, and accordingly, only one hyaluronidase was identified by mass spectrometry in the venom.

PLA~2~ belongs to a superfamily of lipolytic enzymes that catalyze specific hydrolysis of the ester linkage at the *sn-2* position of glycerophospholipids, generating arachidonic acid and lysophospholipids. PLA~2~-like proteins found in snake venoms may be devoid of catalytic activity, although it may exhibit myotoxic or neurotoxic activities \[[@pntd.0007017.ref080], [@pntd.0007017.ref081]\]. Moreover, these enzymes may present with other toxic properties during envenomation, such as the ability to cause cytotoxicity and inflammation \[[@pntd.0007017.ref082], [@pntd.0007017.ref083]\]. As predicted by LC-MS/MS, the presence of PLA~2~ activity in *N*. *annulifera* venom was also observed in enzymatic assays. Nonetheless, *N*. *annulifera* venom exhibits a very lower content of PLA2 /enzymatic activity when compared to other *Naja* venoms \[[@pntd.0007017.ref084], [@pntd.0007017.ref085], [@pntd.0007017.ref086], [@pntd.0007017.ref087], [@pntd.0007017.ref088]\], suggesting a strong interspecific variation associated to this particular toxin.

As observed in dogs, we showed here that *N*. *annulifera* venom promoted hemostatic disturbances in human plasma, making it incoagulable. These disturbances in the hemostatic system can be attributed to the fibrinogenolytic proteinases detected in the venom, or to PLA~2~ found in the LC-MS/MS analysis, since these components can promote plasma incoagulability via direct binding to FXa, thereby preventing thrombin generation \[[@pntd.0007017.ref089], [@pntd.0007017.ref090], [@pntd.0007017.ref091], [@pntd.0007017.ref092]\]. This phenomenon, promoted by several species of *Naja* venom, has been observed in different clinical and experimental studies \[[@pntd.0007017.ref093], [@pntd.0007017.ref094]\]. It is therefore very important to evaluate the mechanisms involved in these alterations and their consequence, since the current literature on the topic is scarce. In addition, these alterations may be a therapeutic target for *Naja* envenomation.

In our *in vivo* experimental model, the venom was able to induce swelling and several histopathologic changes in the hind paws of mice, that decreased only after 24 hours. Among these tissue alterations, myonecrosis associated with inflammation was observed, an event that is commonly found in experimental models of Elapidae envenomation, which is attributed to cytotoxins and PLA~2~ \[[@pntd.0007017.ref095], [@pntd.0007017.ref096]\].

The inflammatory events promoted by the venom may be attributed to hyaluronidase, PLA~2~, glycosylated proteins, SVSP and SVMP since they can promote different inflammatory events, which include complement activation, mast cell degranulation, release of eicosanoids and cytokines and leukocyte homing \[[@pntd.0007017.ref016], [@pntd.0007017.ref026], [@pntd.0007017.ref027], [@pntd.0007017.ref058], [@pntd.0007017.ref059], [@pntd.0007017.ref060], [@pntd.0007017.ref061], [@pntd.0007017.ref083]\]. Knowing that *N*. *annulifera* venom promotes inflammation and pain in humans and dogs \[[@pntd.0007017.ref031], [@pntd.0007017.ref032], [@pntd.0007017.ref033], [@pntd.0007017.ref034], [@pntd.0007017.ref035], [@pntd.0007017.ref036]\], which were also observed in our experimental model, pharmacologic studies were performed to analyze the role of some inflammatory mediators in the edema process. Pre-treating mice with different compounds that were able to modulate different steps of the inflammatory process, including, mast cell degranulation (Cromolyn), lipid mediator production (Dexamethasone, Indomethacin and MK-886) and action (WEB-2086) significantly decreased the edema promoted by *N*. *annulifera* venom. All of the compounds showed a similar pattern of inhibiting peak edema. However, cPLA~2~, COX isoforms and FLAP inhibitors controlled the edema for a long time, suggesting a stronger contribution of eicosanoids, such as prostaglandins, thromboxanes and leukotrienes, to this process. Moreover, it is possible that these lipid mediators may contribute to the pain observed in humans after a bite, making them good therapeutic targets for the local reactions promoted by *N*. *annulifera* venom.

The LD~50~ of *N*. *annulifera*, established here via i.p. route in Balb/c mice, was 94.14 μg. Ramos-Cerrillo and collaborators \[[@pntd.0007017.ref056]\] showed that the *N*. *annulifera* venom LD~50~ when administered intravenously was 53.9 μg. To evaluate whether *N*. *annulifera* venom was able to promote systemic changes, a sublethal dose of the venom was established, and different inflammatory parameters were evaluated. As in dogs envenomed by *N*. *annulifera* \[[@pntd.0007017.ref034]\], it was observed that a sublethal dose of the venom promotes acute systemic inflammation, which was characterized by neutrophilia and increased levels of IL-6 and MCP-1 in the plasma. However, unlike dogs envenomed by *N*. *annulifera* the sublethal dose was not able to cause organ injury, as observed by Langhorn et al. \[[@pntd.0007017.ref035]\] in dogs.

By administering a superdose (2LD~50~) of venom to mice, it was possible to observe systemic inflammation, which was characterized by an increase in the plasma levels of IL-6 and MCP-1. However, in contrast with the sublethal dose, the 2DL~50~ dose caused leukocytosis, which was characterized by neutrophilia and monocytosis. In addition, dead animals showed multifocal hemorrhaging in their lungs.

These data suggest that the systemic inflammatory process induced by high doses of venom may be associated with the lung alterations observed in humans. In fact, in different models of hemorrhagic shock, plasma, pulmonary and hepatic increases in IL-6 and MCP-1 were observed along with inflammation and lung injury, which may culminate in acute respiratory distress syndrome \[[@pntd.0007017.ref097], [@pntd.0007017.ref098], [@pntd.0007017.ref099]\]. It is important to emphasize that in addition to cytokines, some other factors may be associated with the pulmonary hemorrhaging and death caused by a venom overdose. Further, the hemostatic alterations promoted by SVMP, SVSP and PLA~2~ can also contribute to lung hemorrhage.

The treatment indicated for envenomation by *N*. *annulifera* is serum therapy. *N*. *annulifera* venom is part of the antigenic mixture used for the production of polyvalent serum by the South African Vaccine Producers (SAVP) (Pty) Ltd \[[@pntd.0007017.ref028]\], although its immunogenicity and neutralizing potential have been poorly investigated. Here, we show that *N*. *annulifera* venom is highly immunogenic in murine model. Although with different intensities, this mouse antivenom was able to recognize venom components by Western Blot, mainly the ones with high molecular weight, which includes components as HYA, LAAO, CVF and SVMP. Moreover, this monovalent antivenom was able to protect the animals from death induced by venom, with high potency. In contrast, other studies have shown that horse antivenoms produced against venom mixtures, in which *N*. *annulifera* was included, were not able to neutralize the lethal effects of this venom \[[@pntd.0007017.ref056], [@pntd.0007017.ref100], [@pntd.0007017.ref101]\]. This may be due to differences related to the animals used (mouse *versus* horse) or to a low level of neutralizing antibodies generated by other venoms present in the immunization pool.

In conclusion, here, we show that *N*. *annulifera* snake venom contains several components with toxic and pro-inflammatory properties. Some of these toxins promote coagulation disturbances, local and systemic inflammatory reactions, which may contribute to the pathologic events, observed in our murine model and possibly in dogs and humans envenomated by *N*. *annulifera*. Moreover, the venom promoted lung haemorrhage, an event that may also occur in cases of human envenomation, since death by respiratory arrest can be the result of the sum of neurotoxin activity and lung haemorrhage. High levels of IL-6 and MCP-1, as detected in the plasma of the envenomated animals, may be associated with pulmonary damage, since systemic inflammatory conditions can be deleterious and affect several organs, including the lungs. Thus, inflammation may be considered as target for the development of new therapeutic strategies in cases of *N*. *annulifera* human envenomation. Moreover, we showed that the venom is highly immunogenic and that the experimental serum was able to neutralize its lethal activity in the murine model. These data encourage further studies to characterize and produce monospecific therapeutic antivenom against *N*. *annulifera*.
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###### Identification of proteins in *N. annulifera* snake venom by trypsin digestion and LC-MS/MS analysis.
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###### Unique peptides identified in the *N. annulifera* snake venom.
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###### Pharmacologic modulation of the edema induced by *N. annulifera* snake venom.

To evaluate the contribution of the different inflammatory mediators classes in hindpaw edema induced by *N*. *annulifera*' s venom, Balb/c mice groups were treated with \[A\] Cromolyn, a mast cell degranulation inhibitor (10 mg/kg, three days consecutively before the edema, i.p. route); \[B\] dexamethasone (Dexa), a cPLA~2~ inhibitor (2 mg/kg, 2 hours before the edema, i.p. route); \[C\] indomethacin (Indo), a COX isoform inhibitor (10 mg/kg, 30 minutes before the edema, i.p. route); \[D\] MK886, a 5-lipoxygenase-activating protein inhibitor (5 mg/kg, 30 minutes before the edema, i.p. route) and \[E\] WEB2086, a PAFR antagonist (5 mg/kg, 1 hour before the edema, s.c. route). After treatment, edema was induced, and the paws were measured with a caliper rule at several time points. The increased paw volume was expressed as percentage. Statistical analysis was performed using two-way ANOVA, followed by the Bonferroni multiple comparison test (\*\*\**p≤* 0.05) ± SD.
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